216 related articles for article (PubMed ID: 37819154)
1. Immunotherapy for myelodysplastic syndrome and acute myeloid leukemia: where do we stand?
Spillane DR; Assouline S
Expert Rev Hematol; 2023; 16(11):819-834. PubMed ID: 37819154
[TBL] [Abstract][Full Text] [Related]
2. BITES and CARS and checkpoints, oh my! Updates regarding immunotherapy for myeloid malignancies from the 2018 annual ASH meeting.
Przespolewski AC; Griffiths EA
Blood Rev; 2020 Sep; 43():100654. PubMed ID: 32029263
[TBL] [Abstract][Full Text] [Related]
3. Update on Immunotherapy in AML and MDS: Monoclonal Antibodies and Checkpoint Inhibitors Paving the Road for Clinical Practice.
Masarova L; Kantarjian H; Ravandi F; Sharma P; Garcia-Manero G; Daver N
Adv Exp Med Biol; 2018; 995():97-116. PubMed ID: 30539507
[TBL] [Abstract][Full Text] [Related]
4. Immunotherapy in acute myeloid leukemia and myelodysplastic syndromes: The dawn of a new era?
Liu Y; Bewersdorf JP; Stahl M; Zeidan AM
Blood Rev; 2019 Mar; 34():67-83. PubMed ID: 30553527
[TBL] [Abstract][Full Text] [Related]
5. Novel immune directed therapies in myelodysplastic syndromes and acute myeloid leukemia.
Brunner AM
Curr Opin Hematol; 2023 Mar; 30(2):38-44. PubMed ID: 36728945
[TBL] [Abstract][Full Text] [Related]
6. Harnessing the Immune System Against Leukemia: Monoclonal Antibodies and Checkpoint Strategies for AML.
Masarova L; Kantarjian H; Garcia-Mannero G; Ravandi F; Sharma P; Daver N
Adv Exp Med Biol; 2017; 995():73-95. PubMed ID: 28321813
[TBL] [Abstract][Full Text] [Related]
7. A Killer Disarmed: Natural Killer Cell Impairment in Myelodysplastic Syndrome.
Arellano-Ballestero H; Sabry M; Lowdell MW
Cells; 2023 Feb; 12(4):. PubMed ID: 36831300
[TBL] [Abstract][Full Text] [Related]
8. Checkpoint Inhibitors and Other Immune-Based Therapies in Acute Myeloid Leukemia.
Haddad F; Zeidan AM; Daver N
Cancer J; 2022 Jan-Feb 01; 28(1):43-50. PubMed ID: 35072373
[TBL] [Abstract][Full Text] [Related]
9. Emerging Immunotherapy for Acute Myeloid Leukemia.
Tabata R; Chi S; Yuda J; Minami Y
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33669431
[TBL] [Abstract][Full Text] [Related]
10. New Frontiers in Monoclonal Antibodies for the Targeted Therapy of Acute Myeloid Leukemia and Myelodysplastic Syndromes.
Gallazzi M; Ucciero MAM; Faraci DG; Mahmoud AM; Al Essa W; Gaidano G; Mouhssine S; Crisà E
Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35886899
[TBL] [Abstract][Full Text] [Related]
11. Immune Therapies for Myelodysplastic Syndromes and Acute Myeloid Leukemia.
Kapoor S; Champion G; Basu A; Mariampillai A; Olnes MJ
Cancers (Basel); 2021 Oct; 13(19):. PubMed ID: 34638510
[TBL] [Abstract][Full Text] [Related]
12. Immune-Based Therapeutic Interventions for Acute Myeloid Leukemia.
Perna F; Espinoza-Gutarra MR; Bombaci G; Farag SS; Schwartz JE
Cancer Treat Res; 2022; 183():225-254. PubMed ID: 35551662
[TBL] [Abstract][Full Text] [Related]
13. The emerging role of immune checkpoint based approaches in AML and MDS.
Boddu P; Kantarjian H; Garcia-Manero G; Allison J; Sharma P; Daver N
Leuk Lymphoma; 2018 Apr; 59(4):790-802. PubMed ID: 28679300
[TBL] [Abstract][Full Text] [Related]
14. Natural killer cell (NK) subsets and NK-like T-cell populations in acute myeloid leukemias and myelodysplastic syndromes.
Aggarwal N; Swerdlow SH; TenEyck SP; Boyiadzis M; Felgar RE
Cytometry B Clin Cytom; 2016 Jul; 90(4):349-57. PubMed ID: 26648320
[TBL] [Abstract][Full Text] [Related]
15. Acute myeloid leukemia and myelodysplastic syndrome associated with a combination of immune checkpoint inhibitor and platinum-based chemotherapy.
Nakatsuru K; Tsubouchi K; Hirahata M; Nakashima T; Takahata Y; Okamatsu Y; Shiraishi Y; Okamoto I; Harada T
Thorac Cancer; 2023 Aug; 14(22):2225-2228. PubMed ID: 37337950
[TBL] [Abstract][Full Text] [Related]
16. Immune Checkpoint Inhibition in Acute Myeloid Leukemia and Myelodysplastic Syndromes.
Abaza Y; Zeidan AM
Cells; 2022 Jul; 11(14):. PubMed ID: 35883692
[TBL] [Abstract][Full Text] [Related]
17. Myelodysplastic syndrome and immunotherapy novel to next in-line treatments.
Linder K; Lulla P
Hum Vaccin Immunother; 2021 Aug; 17(8):2602-2616. PubMed ID: 33941042
[TBL] [Abstract][Full Text] [Related]
18. Natural Killer Immunotherapy for Minimal Residual Disease Eradication Following Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia.
Hattori N; Nakamaki T
Int J Mol Sci; 2019 Apr; 20(9):. PubMed ID: 31027331
[TBL] [Abstract][Full Text] [Related]
19. Secondary myeloid neoplasms after CD19 CAR T therapy in patients with refractory/relapsed B-cell lymphoma: Case series and review of literature.
Zhao A; Zhao M; Qian W; Liang A; Li P; Liu H
Front Immunol; 2022; 13():1063986. PubMed ID: 36713414
[TBL] [Abstract][Full Text] [Related]
20. Adoptive cell therapy for acute myeloid leukemia.
Ma H; Padmanabhan Iyer S; Parmar S; Gong Y
Leuk Lymphoma; 2019 Jun; 60(6):1370-1380. PubMed ID: 30628504
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
